Company news
Immunitybio, Inc. (NASDAQ:IBRX) news
Immunitybio, Inc. news releases on 6ix. Latest, May 13, 2021: CytRx Comments on Quarterly Results and Year-to-Date Progress
Press releases — page 4
CytRx Comments on Quarterly Results and Year-to-Date Progress
May 12, 2021
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients
May 3, 2021
ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs
April 28, 2021
ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications
April 21, 2021
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
April 7, 2021
ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors
March 31, 2021
ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer
March 28, 2021
ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors
March 21, 2021
ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations
March 14, 2021
ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses
March 10, 2021
ImmunityBio and NantKwest Complete Merger
March 8, 2021
Stockholders of NantKwest Approve Merger With ImmunityBio
March 7, 2021
ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.
March 7, 2021
ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors
February 23, 2021
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio
February 23, 2021
ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate
February 15, 2021
ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
February 10, 2021
ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer
January 27, 2021
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
January 12, 2021
NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
January 5, 2021
ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
December 20, 2020
ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
December 20, 2020
ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
December 9, 2020
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
November 22, 2020
NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference
November 17, 2020
ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
November 9, 2020
ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2
November 8, 2020
NantKwest Names Richard Adcock Chief Executive Officer
October 25, 2020
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2
October 20, 2020
FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity
October 14, 2020
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care
October 5, 2020
NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit
September 20, 2020
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
August 23, 2020
Cord Blood Registry (CBR®) By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment
August 9, 2020
ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
August 2, 2020
NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 28, 2020
NantKwest Announces Pricing of Public Offering of Common Stock
June 24, 2020
NantKwest Announces Proposed Public Offering of Common Stock
June 23, 2020
NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested
June 9, 2020
ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
May 26, 2020
NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
May 25, 2020
NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
May 17, 2020
NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
May 13, 2020
NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
April 28, 2020
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter
April 13, 2020
NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
March 18, 2020
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
January 13, 2020
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS
December 15, 2019
NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
December 1, 2019
NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors
November 26, 2019